Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

The jab has already been hailed a breakthrough in the war on obesity. Now, US researchers have found those on the injections ...

Mounjaro (tirzepatide) is a newly approved medication for type 2 diabetes by the FDA. It belongs to a novel class of drugs ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

(CNN) — For years, the shortage of certified air traffic controllers in the US has led to flight disruptions and headaches for travelers across the country, most recently at busy Newark Liberty ...

Zepbound (tirzepatide) is a type of drug called a glucagon-like peptide-1 (GLP-1) receptor agonist. It has the same active ingredient as the type 2 diabetes medication Mounjaro. The Food and Drug ...